Short Interest in Lumos Pharma, Inc. (NASDAQ:LUMO) Decreases By 33.3%

Lumos Pharma, Inc. (NASDAQ:LUMO) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 308,300 shares, a decline of 33.3% from the August 15th total of 462,300 shares. Based on an average daily trading volume, of 76,100 shares, the days-to-cover ratio is currently 4.1 days. Currently, 5.8% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Oppenheimer lowered their price target on Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, August 2nd.

Lumos Pharma Trading Down 1.5 %

NASDAQ:LUMO traded down $0.06 during trading hours on Monday, hitting $3.87. The stock had a trading volume of 36,209 shares, compared to its average volume of 44,406. Lumos Pharma has a 1-year low of $1.37 and a 1-year high of $4.55. The business has a 50 day simple moving average of $2.59 and a two-hundred day simple moving average of $2.62. The company has a market cap of $31.41 million, a PE ratio of -0.84 and a beta of 0.78.

Lumos Pharma (NASDAQ:LUMO) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.33. Lumos Pharma had a negative net margin of 2,405.72% and a negative return on equity of 157.99%. The company had revenue of $0.49 million during the quarter. During the same period last year, the business earned ($1.09) EPS. Research analysts expect that Lumos Pharma will post -2.56 EPS for the current fiscal year.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.